The Wall Street Journal reports:
A Chinese vaccine candidate showed to be 86% effective in protecting people against Covid-19, according to interim results of a Phase 3 trial in the United Arab Emirates, in a boost for China as it races with Western nations to slow the spread of the coronavirus.
The U.A.E. said it has registered the vaccine from state-owned Sinopharm, according to a statement on the country’s official news agency. It began Phase 3 trials in July of Sinopharm’s vaccine and began emergency use three months later.
The analysis showed 99% of participants developed antibodies against the disease, the statement said. The vaccine candidate from Sinopharm, or China National Pharmaceuticals Group, is based on an inactivated virus, meaning that the pathogen is weakened for use on humans.
The above-linked report is behind a paywall.
The United Arab Emirates said China’s Sinopharm’s Covid-19 vaccine has an 86% efficacy against the coronavirus, state-run WAM reported on Wednesday https://t.co/yDIEqVkVbu
— Bloomberg (@business) December 9, 2020